www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Allergy immunotherapy
    • Healthcare professionals
      • Reweal
      • Webinars
    • Pipeline
    • Clinical trials
    • Clinical data sharing
  • Our company
    • Newsroom
      • Stories
    • Privacy
    • Global presence
    • Organisation
    • History
    • Owners
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Board of Management
      • Board of Directors
      • Annual general meeting
      • Annual general meeting (DK)
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
      • ADR Programme
    • Contact IR
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

Company releases

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
DateTitle
21-12-2022 2:35 EST Henriette Mersebach to succeed Henrik Jacobi as Executive Vice President, R&D at ALK
19-12-2022 11:33 EST ALK – Financial calendar for the 2023 financial year
30-11-2022 11:24 EST Management change at ALK
10-11-2022 1:30 EST Nine-month interim report (Q3) 2022
3-11-2022 9:16 EDT Release date of nine-month interim report (Q3) 2022 for ALK and audio cast
25-8-2022 11:13 EDT Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
16-8-2022 10:49 EDT Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
11-8-2022 1:29 EDT Six-month interim report (Q2) 2022
4-8-2022 9:33 EDT Release date of six-month interim report (Q2) 2022 for ALK and audio cast
4-8-2022 7:38 EDT ALK upgrades its full-year financial outlook
3-7-2022 6:45 EDT ALK spotlights the impact of respiratory allergies on children at EAACI Congress
27-6-2022 6:45 EDT ALK begins clinical trial of its SLIT-tablet for the treatment of peanut allergy
19-5-2022 12:15 EDT Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
17-5-2022 14:43 EDT Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
12-5-2022 1:30 EDT Three-month interim report (Q1) 2022
3-5-2022 5:29 EDT Release date of three-month interim report (Q1) 2022 for ALK and audio cast
29-3-2022 4:30 EDT Total share capital and voting rights
24-3-2022 12:15 EDT Grant of share options and performance shares to members of the Board of Management and key employees
16-3-2022 14:18 EDT Decision to complete share split at a ratio of 1:20
16-3-2022 12:58 EDT Annual General Meeting in ALK-Abelló A/S held on 16 March 2022
3-3-2022 6:33 EST Clinical trial waiver in China opens door to 2022 registration filing for ALK’s dust mite allergy tablet
2-3-2022 11:03 EST Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
21-2-2022 8:00 EST Annual General Meeting in ALK-Abelló A/S on 16 March 2022
8-2-2022 1:29 EST Annual report 2021: ALK delivers strong sales growth of 12% with tablet sales up 29% and EBITDA up 35%
3-2-2022 3:40 EST Release date of annual report 2021 for ALK and audio cast
 
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved